Juno Therapeutics (JUNO) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Juno Therapeutics Reports First Quarter 2015 Financial Results
May 11, 2015 4:06 PM EDTConference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time
- Positive momentum on clinical trials and research continues - Multiple strategic transactions further strengthen technology platform and capabilities - Strong quarter-end cash position of $447.6 million - Affirmed 2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and now-settled litigation
SEATTLE, May 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to... More
Juno Therapeutics Strengthens Multiple Capabilities Through Acquisition of Stage Cell Therapeutics
May 11, 2015 4:02 PM EDTTransaction Provides Transformative Cell Selection and Activation Capabilities, Advanced Manufacturing Automation, Improved Supply Chain, and Lower Expected Cost of Goods Initial Payment of 52.5 Million in Cash (Approximately $59 Million) and 486,279 Shares of Juno Stock
SEATTLE, May 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced today that it has acquired Stage Cell Therapeutics GmbH ("Stage"), a privately held biotechnology company based in Munich and Göttingen, Germany. The transaction furthers Juno's strategy of being a world leader in... More
